STE · Full Picture

STERIS plc — the full picture

Earnings window · 2026-07-17 to 2026-08-10 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

1. Segment Revenue Performance · Revenue growth & mixPriority 78
   +18.0% revenue (realized); 3 sources (news, press_release, sec_filing); structured_verified
   Total recurring revenues in Q1 FY2027 were $1,229.6 million (consumables $474.0 million and service $755.5 million) and capital equipment revenue was $263.2 million.
2. Guidance / Outlook · Guidance & outlookPriority 77
   +6.4% revenue; 2 sources (news, press_release); 3 forward row(s); quote_verified
   Adjusted net income from continuing operations per diluted share for FY 2027 is estimated at $11.10 - $11.30, with net income from continuing operations per diluted share estimated at $8.92 - $9.12 and adjustments for amortization of acquired intangible assets of 2.08 and restructuring charges of 0.07.
3. Headcount / Restructuring · Restructuring & impairmentPriority 68
   -3.6% operating_income; 2 sources (news, sec_filing); 6 forward row(s); quote_verified
   The August 5, 2026 restructuring is expected to incur total pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges; completion anticipated during fiscal 2030.
4. Capital Expenditure Outlook · UnclassifiedPriority 66
   2 forward row(s); quote_verified
   Capital expenditures are now anticipated to be approximately $450 million compared with prior expectations of $375 million.
5. Operating Cash Flow Trends · Cash flow generationPriority 65
   2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
   Free cash flow for fiscal 2027 is now expected to be approximately $800 million compared with prior expectations of $850 million.
6. Products and Technology · Products & launchesPriority 62
   2 sources (press_release, sec_filing); quote_verified
   The August 5, 2026 restructuring investment strengthens Healthcare and Life Sciences formulated chemistries businesses, which together generate more than $700 million in annual revenue.
7. Restructuring and Facility Consolidation · Restructuring & impairmentPriority 60
   -3.5% operating_income; 2 forward row(s); quote_verified
   The Company currently expects to incur total pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges.
8. Manufacturing and Capacity · Supply chain & operationsPriority 57
   3 sources (news, press_release, sec_filing); quote_verified
   The new North Carolina facility is expected to become operational in 2-3 years.
9. North Carolina Chemistry Investment · UnclassifiedPriority 57
   +2.8% assets; 3 forward row(s); quote_verified
   STERIS outlined a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina.
10. Geographic Market Commentary · Geographic mixPriority 56
    +6.4% revenue (realized); quote_verified
    United States revenues for the three months ended June 30, 2026: $1,090.6 million, compared to $1,025.6 million for the three months ended June 30, 2025 (6.3% increase).
11. Operating Expense Trends · Operating expenses (SG&A)Priority 55
    2 sources (press_release, sec_filing); quote_verified
    Selling, general, and administrative (SG&A) expenses for the three months ended June 30, 2026: $369.7 million, compared to $353.8 million for the three months ended June 30, 2025 (4.5% increase).
12. Market Demand Trends · Demand, orders & backlogPriority 52
    2 sources (news, press_release); quote_verified
    Investing.com noted analysts are watching Applied Sterilization Technologies (AST) for signs of stabilizing after destocking and anticipated STERIS earnings of $2.50 and revenue of $1.5 billion.

Threads by pillar

Revenue & Demand Priority 87 · 4 threads

• Segment Revenue PerformancePriority 78 · News, Release, Filing
• Products and TechnologyPriority 62 · Release, Filing
• Geographic Market CommentaryPriority 56 · Filing
• Market Demand TrendsPriority 52 · News, Release

Costs & Margins Priority 88 · 7 threads

• Headcount / RestructuringPriority 68 · News, Filing
• Restructuring and Facility ConsolidationPriority 60 · Release
• Segment ProfitabilityPriority 49 · Release
• Operating Income and MarginsPriority 43 · Filing
• Manufacturing and CapacityPriority 57 · News, Release, Filing
• Operating Expense TrendsPriority 55 · Release, Filing
• Gross Margin DriversPriority 48 · Release, Filing

Capital & Balance Sheet Priority 79 · 5 threads

• Operating Cash Flow TrendsPriority 65 · Release, Filing
• Income Tax Rate ChangesPriority 49 · Release, Filing
• Capital Return ProgramPriority 45 · Release, Filing
• Dividend IncreasePriority 32 · News
• Liquidity and Debt PositionPriority 40 · Release, Filing

Strategy & Portfolio Priority 36 · 1 thread

• Acquisition / Partnership / DivestiturePriority 36 · Release, Filing

Legal, Regulatory & Policy Priority 34 · 1 thread

• Trade Policy and TariffsPriority 34 · Filing

Guidance & Outlook Priority 77 · 1 thread

• Guidance / OutlookPriority 77 · News, Release

Macro & Market Conditions Priority 24 · 1 thread

• Inflation Cost PressurePriority 24 · Filing

Unclassified Priority 71 · 3 threads

• Capital Expenditure OutlookPriority 66 · Release
• North Carolina Chemistry InvestmentPriority 57 · News
• Capital Expenditures and Free Cash FlowPriority 48 · News

Expected impact by metric